Lumen Bioscience Strengthens Leadership for Future Innovations
Expansion follows significant funding round led by WestRiver Group.
SEATTLE – Lumen Bioscience, a forward-thinking biotech dedicated to developing innovative orally delivered biologics, has announced pivotal changes in its leadership team to further enhance its clinical pipeline.
In a strategic move to boost its operational capabilities, Lumen has appointed Jeff Raikes to its board as an independent director. Raikes, known for his exemplary career at Microsoft, where he played an essential role in creating significant software platforms, brings a wealth of knowledge about technology innovation and extensive experience in large-scale business operations. His background at Costco has also provided him insights into global distribution, which will prove invaluable as Lumen prepares to commercialize its innovative product range.
Additional noteworthy updates in the leadership team include the promotion of Nhi Khuong, PhD, to Executive Vice President and Kole Krieger to Senior Vice President. Joining the clinical development team is David Saunders, MD, MPH, who has a distinguished career as a Colonel and clinical trialist in the U.S. Army. Furthermore, Erik Anderson has been elected Vice Chairman of the board, working closely with board co-chairs and co-founders Brian Finrow and Jim Roberts. Lumen's team has seen substantial growth, expanding by nearly 39% since 2023 while establishing a second dedicated GMP facility to meet the increasing demand for clinical trial drug supplies.
Funding and Future Directions
The recent enhancements in leadership are complemented by the completion of an oversubscribed $30 million Series C financing extension, led by WestRiver Group. This round secured significant backing from the Gates Foundation and existing investors. The new investors joining the consortium include distinguished individuals such as Matt Horner, Executive Vice President of Global Enterprise at World Wide Technology, and David Siegel, Co-Founder and Co-Chairman of Two Sigma.
With this fresh funding, Lumen will accelerate its late-stage clinical programs and activities aimed at achieving commercial readiness. These steps follow the positive outcomes reported in the ongoing Phase 2 segment of the RePreve Clinical Trial for investigational LMN-201, which targets recurrent C. difficile infections.
Brian Finrow, CEO of Lumen Bioscience, expressed excitement about these developments: "This milestone affirms the transformative power of spirulina-based GMP manufacturing. As our clinical programs progress, we're focusing more on commercialization and distribution. Our new investors have substantial experience in building impactful organizations, and we're eager to leverage their insights while advancing Lumen’s mission."?
Investing in Transformative Innovations
Erik Anderson, Founder and CEO of WestRiver Group, emphasized their commitment to investing in revolutionary innovations in drug delivery. "Lumen’s approach to biologics for oral gastrointestinal delivery represents a breakthrough in medicine, making effective therapeutics more accessible and cost-effective for billions worldwide. Together, we are redefining treatment paradigms, empowering patients, and improving health outcomes."?
About Lumen Bioscience
Seattle-based Lumen Bioscience, Inc. has pioneered a spirulina-based platform for drug discovery, manufacturing, and delivery, targeting various high prevalence diseases and disorders that conventional biopharmaceuticals struggle to address. This platform not only accelerates the speed of drug development but also enables straightforward assembly of therapeutic cocktails, allowing for mass-market scaling at lower costs. Lumen is advancing investigational oral biologic drugs and dietary supplements designed for local gut action, with pipelines addressing issues like weight loss, C. difficile infections, inflammatory bowel disease, and more.
About WestRiver Group
WestRiver Group operates as a thematically-driven investment platform focused on fostering innovation within the global economy. Backed by influential investors, it directs funding towards companies that leverage innovative strategies to positively impact society. Continuing its mission from Seattle, WestRiver passionately invests in technology advancements spanning biosciences, sustainability, and digital transformation.
Frequently Asked Questions
What recent changes occurred at Lumen Bioscience?
Lumen Bioscience has expanded its leadership team, appointing notable figures such as Jeff Raikes and promoting Nhi Khuong to Executive Vice President.
How much funding did Lumen Bioscience recently secure?
Lumen completed a $30 million Series C financing extension to further its clinical pipeline and operational growth.
Who are the key investors in Lumen's recent funding round?
WestRiver Group led the funding round, with significant participation from the Gates Foundation and other influential investors.
What is Lumen's focus in terms of product development?
Lumen primarily focuses on developing oral biologics aimed at treating various gastrointestinal diseases and disorders.
What impact do these leadership changes have on Lumen's operations?
These changes aim to enhance Lumen’s operational efficiency and guide the company towards commercial readiness for its innovative products.
